GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (LTS:0M26) » Definitions » EV-to-EBITDA

XOMA Royalty (LTS:0M26) EV-to-EBITDA : -15.82 (As of Dec. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is XOMA Royalty EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, XOMA Royalty's enterprise value is $296.06 Mil. XOMA Royalty's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-18.71 Mil. Therefore, XOMA Royalty's EV-to-EBITDA for today is -15.82.

The historical rank and industry rank for XOMA Royalty's EV-to-EBITDA or its related term are showing as below:

LTS:0M26' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5163.48   Med: -5.55   Max: 275.95
Current: -15.82

During the past 13 years, the highest EV-to-EBITDA of XOMA Royalty was 275.95. The lowest was -5163.48. And the median was -5.55.

LTS:0M26's EV-to-EBITDA is ranked worse than
100% of 452 companies
in the Biotechnology industry
Industry Median: 9.27 vs LTS:0M26: -15.82

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-14), XOMA Royalty's stock price is $29.00. XOMA Royalty's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.480. Therefore, XOMA Royalty's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


XOMA Royalty EV-to-EBITDA Historical Data

The historical data trend for XOMA Royalty's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty EV-to-EBITDA Chart

XOMA Royalty Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,512.94 31.66 8.69 -8.97 -4.67

XOMA Royalty Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.95 -4.67 -7.59 -24.73 -15.36

Competitive Comparison of XOMA Royalty's EV-to-EBITDA

For the Biotechnology subindustry, XOMA Royalty's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA Royalty's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's EV-to-EBITDA falls into.



XOMA Royalty EV-to-EBITDA Calculation

XOMA Royalty's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=296.058/-18.714
=-15.82

XOMA Royalty's current Enterprise Value is $296.06 Mil.
XOMA Royalty's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XOMA Royalty  (LTS:0M26) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

XOMA Royalty's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=29.00/-3.480
=At Loss

XOMA Royalty's share price for today is $29.00.
XOMA Royalty's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.480.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


XOMA Royalty EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA Royalty Business Description

Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA Royalty Headlines

No Headlines